Advertisement
Screener

Spruce Biosciences, Inc. (SPRB) Repayments of Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

Spruce Biosciences, Inc. Repayments of Long-Term Debt

Spruce Biosciences, Inc. (SPRB) reported Repayments of Long-Term Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Financing Activities

us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-12

  • Spruce Biosciences, Inc. repayments of long-term debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
  • Spruce Biosciences, Inc. repayments of long-term debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
  • Spruce Biosciences, Inc. repayments of long-term debt for the quarter ending 2025-12-31 was $841.00K, a 107.14% increase year-over-year.
  • Spruce Biosciences, Inc. repayments of long-term debt for the quarter ending 2025-09-30 was $405.00K, a 0.00% change year-over-year.
  • Spruce Biosciences, Inc. repayments of long-term debt for fiscal 2025 was $2.06M, a 26.82% increase from fiscal 2024.
  • Spruce Biosciences, Inc. repayments of long-term debt for fiscal 2024 was $1.62M, a 0.00% change from fiscal 2023.
  • Spruce Biosciences, Inc. repayments of long-term debt for fiscal 2023 was $1.62M.
  • Spruce Biosciences, Inc. repayments of long-term debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
Period endRepayments of Long-term Debt 3 monthRepayments of Long-term Debt 6 monthRepayments of Long-term Debt 9 monthRepayments of Long-term Debt 12 month
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$0.00
10-Q · filed 2026-08-12
$841.00K
derived: sum of 3 quarters · filed 2026-08-12
$1.25M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$0.00
10-Q · filed 2026-05-13
$841.00K
derived: sum of 2 quarters · filed 2026-05-13
$1.25M
derived: sum of 3 quarters · filed 2026-05-13
$1.65M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$841.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$1.25M
derived: sum of 2 quarters · filed 2026-03-09
$1.65M
derived: sum of 3 quarters · filed 2026-08-12
$2.06M
10-K · filed 2026-03-09
2025-09-30$405.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$811.00K
derived: sum of 2 quarters · filed 2026-08-12
$1.22M
10-Q · filed 2025-11-10
$1.62M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$406.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$811.00K
10-Q · filed 2026-08-12
$1.22M
derived: sum of 3 quarters · filed 2026-08-12
$1.62M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$405.00K
10-Q · filed 2026-05-13
$811.00K
derived: sum of 2 quarters · filed 2026-05-13
$1.22M
derived: sum of 3 quarters · filed 2026-05-13
$1.62M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$406.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$811.00K
derived: sum of 2 quarters · filed 2026-03-09
$1.22M
derived: sum of 3 quarters · filed 2026-03-09
$1.62M
10-K · filed 2026-03-09
2024-09-30$405.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$811.00K
derived: sum of 2 quarters · filed 2025-11-10
$1.22M
10-Q · filed 2025-11-10
$1.62M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$406.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$811.00K
10-Q · filed 2025-08-14
$1.22M
derived: sum of 3 quarters · filed 2025-08-14
$1.62M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$405.00K
10-Q · filed 2025-05-06
$811.00K
derived: sum of 2 quarters · filed 2025-05-06
$1.22M
derived: sum of 3 quarters · filed 2025-05-06
$1.62M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$406.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
$811.00K
derived: sum of 2 quarters · filed 2025-04-15
$1.22M
derived: sum of 3 quarters · filed 2025-04-15
$1.62M
10-K · filed 2025-04-15
2023-09-30$405.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$811.00K
derived: sum of 2 quarters · filed 2024-11-12
$1.22M
10-Q · filed 2024-11-12
$1.22M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$406.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
$811.00K
10-Q · filed 2024-08-12
$811.00K
derived: sum of 3 quarters · filed 2024-08-12
$811.00K
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31$405.00K
10-Q · filed 2024-05-13
$405.00K
derived: sum of 2 quarters · filed 2024-05-13
$405.00K
derived: sum of 3 quarters · filed 2024-05-13
$405.00K
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
$0.00
derived: sum of 2 quarters · filed 2024-03-18
$0.00
derived: sum of 3 quarters · filed 2024-03-18
$0.00
10-K · filed 2024-03-18
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$0.00
derived: sum of 2 quarters · filed 2023-11-13
$0.00
10-Q · filed 2023-11-13
$0.00
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
$0.00
10-Q · filed 2023-08-14
$0.00
derived: sum of 3 quarters · filed 2023-08-14
$0.00
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$0.00
10-Q · filed 2023-05-15
$0.00
derived: sum of 2 quarters · filed 2023-05-15
$0.00
derived: sum of 3 quarters · filed 2023-05-15
$0.00
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
$0.00
derived: sum of 2 quarters · filed 2023-03-16
$0.00
derived: sum of 3 quarters · filed 2023-03-16
$4.77M
10-K · filed 2023-03-16
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$0.00
derived: sum of 2 quarters · filed 2022-11-10
$4.77M
10-Q · filed 2022-11-10
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
$4.77M
10-Q · filed 2022-08-10
2021-03-31$4.77M
10-Q · filed 2022-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Annexon, Inc. (ANNX)United States$0.147B-4.22
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88